Qiagen N.V. revenue

Qiagen N.V.'s revenue was $2.09bn in fiscal 2025, up 5.7% on the year before. Since fiscal 2009 ($1.01bn) it has grown at a compound 4.7% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Qiagen N.V.: revenue history, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	1,010	1,087	1,170	1,254	1,302	1,345	1,281	1,338	1,418	1,502	1,526	1,870	2,252	2,142	1,965	1,978	2,090
Growth on the year before	—	+7.7%	+7.6%	+7.2%	+3.8%	+3.3%	−4.7%	+4.5%	+5.9%	+5.9%	+1.6%	+22.5%	+20.4%	−4.9%	−8.2%	+0.7%	+5.7%
Gross profit	667	716	750	824	815	865	827	845	923	1,001	1,005	1,233	1,451	1,385	1,234	967	1,299
Gross margin	66.1%	65.8%	64.1%	65.7%	62.6%	64.3%	64.5%	63.1%	65.1%	66.6%	65.9%	65.9%	64.4%	64.7%	62.8%	48.9%	62.2%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Life Sciences Tools & Services: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Qiagen N.V.	$2.09bn	5.7%	17.1%
Bio-rad Laboratories, Inc.	$2.59bn	1.4%	-2.2%
Fortrea Holdings Inc.	$2.67bn	-3.4%	0.4%
Medpace Holdings, Inc.	$2.84bn	20.4%	16.8%
Bruker Corp	$3.50bn	1.6%	8.8%
Sotera Health Co	$1.22bn	8.1%	7.6%

Compare with peers

Head to head: BIO vs QGEN FTRE vs QGEN MEDP vs QGEN

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Qiagen N.V.'s SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Qiagen N.V.